Media Relations News Releases Year: - Any -201820172016 Items per page 102550 Sep 16, 2017 Summary ToggleNovartis’ Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption Sep 13, 2017 Summary ToggleNovartis’ Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data Sep 7, 2017 Summary ToggleNovartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies Aug 30, 2017 Summary ToggleNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Aug 27, 2017 Summary ToggleNovartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk Aug 27, 2017 Summary ToggleNovartis announces exploratory analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned Aug 24, 2017 Summary ToggleNovartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Jul 25, 2017 Summary ToggleSandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries Jul 6, 2017 Summary ToggleNovartis receives approval in the EU for Cosentyx® label update, includes long term superiority data versus Stelara® in psoriasis Jun 23, 2017 Summary ToggleNovartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Pagination First page First Previous page Previous … Page 4 Current page 5 Page 6 Page 7 … Next page Next Last page Last
